Explore the latest research on the role of IGF-1 in cancer development and progression. Find articles on Igf 1 cancer pubmed, including studies on the effects of IGF-1 on tumor growth, metastasis, and resistance to therapy. Stay up to date with the latest findings in cancer research.
| Payment: | Bitcoin, LiteCoin, Zelle, Credit Cards, Western Union, MoneyGram |
| Delivery: | Express (2-5 days), Fedex, DHL |
| Prescription: | OVER THE COUNTER |
| Where to Buy STEROIDS online? | https://max-steroids.com |
According to PubMed, there is a connection between Igf 1 and cancer. Igf 1, also known as insulin-like growth factor 1, is a hormone that plays a role in cell growth and division. Studies have shown that high levels of Igf 1 in the body may increase the risk of developing certain types of cancer.
Igf 1 contributes to the development of cancer by promoting cell growth and division. When Igf 1 levels are high, it can stimulate the growth of cancer cells and help them spread throughout the body. This can lead to the formation of tumors and the progression of cancer.
High levels of Igf 1 have been associated with an increased risk of developing certain types of cancer, including breast cancer, prostate cancer, and colorectal cancer. However, more research is needed to fully understand the relationship between Igf 1 and these specific types of cancer.
Yes, there are several ways to lower Igf 1 levels in the body. One way is through dietary changes, such as reducing the consumption of high-protein foods. Another way is through exercise, as regular physical activity has been shown to lower Igf 1 levels. Additionally, some medications and treatments may also help lower Igf 1 levels, but these should be discussed with a healthcare professional.
Igf 1 has been studied as a potential biomarker for cancer, but its use as a diagnostic tool is still being investigated. While high levels of Igf 1 have been associated with an increased risk of cancer, it is not currently used as a definitive marker for the disease. Other biomarkers, such as specific proteins or genetic mutations, are currently more commonly used for cancer diagnosis.
There is ongoing research exploring the link between Igf 1 and cancer treatment. Some studies have suggested that targeting Igf 1 signaling pathways may be a potential strategy for treating certain types of cancer. However, more research is needed to fully understand how Igf 1 can be effectively targeted in cancer treatment.
Lowering Igf 1 levels in the body may have potential side effects, as Igf 1 plays a role in various physiological processes. Some potential side effects may include changes in bone density, muscle mass, and metabolism. It is important to work with a healthcare professional when considering methods to lower Igf 1 levels to ensure any potential risks or side effects are properly managed.
There are several lifestyle changes that can help reduce the risk of cancer associated with Igf 1. These include maintaining a healthy weight, engaging in regular physical activity, eating a balanced diet that is low in processed foods and high in fruits and vegetables, and avoiding tobacco and excessive alcohol consumption. These lifestyle changes can help lower Igf 1 levels and reduce the risk of developing cancer.
According to PubMed, there is a connection between Igf 1 and cancer. Igf 1, also known as insulin-like growth factor 1, is a hormone that plays a role in cell growth and division. It has been found that high levels of Igf 1 can promote the growth and spread of cancer cells. This hormone can stimulate the growth of tumors and inhibit the body’s natural defense mechanisms against cancer. Therefore, the connection between Igf 1 and cancer suggests that targeting Igf 1 signaling pathways could be a potential strategy for cancer treatment.
Igf 1 promotes the growth of cancer cells through various mechanisms. Firstly, Igf 1 can stimulate cell proliferation, which means it can cause cancer cells to divide and multiply at a faster rate. Secondly, Igf 1 can inhibit apoptosis, which is the process of programmed cell death. This means that cancer cells can survive and continue to grow even when they should naturally die. Additionally, Igf 1 can enhance the invasiveness and metastasis of cancer cells, allowing them to spread to other parts of the body. These mechanisms collectively contribute to the promotion of cancer growth by Igf 1.
Yes, targeting Igf 1 signaling pathways could be a potential treatment for cancer. By inhibiting the activity of Igf 1 or its receptors, it is possible to disrupt the growth-promoting effects of this hormone on cancer cells. Several studies have shown promising results in preclinical models, where blocking Igf 1 signaling has led to the inhibition of tumor growth and increased sensitivity to other cancer treatments. However, more research is needed to fully understand the effectiveness and safety of targeting Igf 1 in cancer treatment. Clinical trials are currently underway to evaluate the potential of Igf 1 inhibitors as a therapeutic approach for various types of cancer.
Igf 1 cancer pubmed: The Connection Between Igf 1 and Cancer According to PubMed
PubMed is a widely recognized and respected database that provides access to a vast collection of scientific articles and research papers. One of the topics extensively studied and documented on PubMed is the connection between Igf 1 and cancer. Igf 1, or insulin-like growth factor 1, is a hormone that plays a crucial role in cell growth and development. It is produced by the liver and acts as a mediator of the effects of growth hormone.
Over the years, researchers have been investigating the relationship between Igf 1 and cancer, trying to understand the potential implications of this hormone on the development and progression of various types of cancer. Numerous studies have shown that elevated levels of Igf 1 are associated with an increased risk of developing certain types of cancer, including breast, prostate, and colorectal cancer.
Furthermore, research conducted on animal models has provided valuable insights into the mechanisms through which Igf 1 can promote tumor growth and metastasis. It has been observed that Igf 1 stimulates cell proliferation, inhibits apoptosis (programmed cell death), and enhances angiogenesis (the formation of new blood vessels) – all of which are essential processes for tumor progression.
While the exact mechanisms underlying the connection between Igf 1 and cancer are still being explored, the evidence gathered from various studies published on PubMed suggests a significant association between elevated Igf 1 levels and an increased risk of cancer development and progression. This knowledge opens up new avenues for potential therapeutic interventions targeting Igf 1 and its signaling pathways, with the aim of inhibiting tumor growth and improving patient outcomes.
According to studies published on PubMed, there is a significant connection between Igf 1 (Insulin-like Growth Factor 1) and cancer. Igf 1 is a protein that plays a crucial role in cell growth and division. It is produced by the liver and other tissues in response to the release of growth hormone.
Several studies have shown that elevated levels of Igf 1 in the body can increase the risk of developing various types of cancer. One study conducted on prostate cancer patients found that higher levels of Igf 1 were associated with a higher risk of aggressive prostate cancer.
Another study focused on breast cancer and found that Igf 1 levels were significantly higher in breast cancer patients compared to healthy individuals. The study also found that higher Igf 1 levels were associated with a worse prognosis and a higher likelihood of recurrence.
Furthermore, research has shown that Igf 1 can promote tumor growth and metastasis. It can stimulate the proliferation of cancer cells and inhibit apoptosis, which is the natural process of programmed cell death. This means that Igf 1 can contribute to the survival and growth of cancer cells.
However, it is important to note that Igf 1 alone is not the sole cause of cancer. It is a complex interaction between various factors, including genetic predisposition, lifestyle choices, and environmental factors. Nevertheless, the evidence suggests that Igf 1 plays a significant role in cancer development and progression.
Understanding the connection between Igf 1 and cancer can help in the development of targeted therapies and interventions. By targeting the Igf 1 pathway, it may be possible to inhibit the growth and spread of cancer cells. This could potentially lead to improved treatment options and outcomes for cancer patients.
| Study 1 | Prostate Cancer | Elevated Igf 1 levels associated with higher risk of aggressive prostate cancer |
| Study 2 | Breast Cancer | Higher Igf 1 levels in breast cancer patients, associated with worse prognosis and higher likelihood of recurrence |
| Study 3 | Various Cancer Types | Igf 1 promotes tumor growth and metastasis, stimulates cancer cell proliferation, and inhibits apoptosis |
In conclusion, the studies published on PubMed provide evidence for the connection between Igf 1 and cancer. Elevated levels of Igf 1 can increase the risk of developing various types of cancer and contribute to cancer progression. Further research is needed to fully understand the mechanisms underlying this connection and to develop effective treatment strategies.
According to studies published on PubMed, there is a strong connection between Insulin-like Growth Factor 1 (IGF-1) and cancer development. IGF-1 is a hormone that plays a crucial role in cell growth and division, and it is often found to be elevated in individuals with various types of cancer.
Research has shown that individuals with higher levels of IGF-1 in their blood have an increased risk of developing certain types of cancer. This hormone promotes cell growth and proliferation, and when its levels are elevated, it can contribute to the uncontrolled growth of cancer cells.
One study published in the Journal of the National Cancer Institute found that high levels of IGF-1 were associated with an increased risk of prostate cancer in men. Another study published in the British Journal of Cancer found a positive correlation between IGF-1 levels and the risk of breast cancer in premenopausal women.
IGF-1 exerts its effects on cell growth and division through a signaling pathway that involves several proteins and receptors. Dysregulation of this pathway can lead to abnormal cell proliferation and contribute to cancer development and progression.
Several studies have shown that the IGF-1 signaling pathway is frequently altered in various types of cancer. For example, mutations in the genes encoding the IGF-1 receptor have been found in certain types of lung cancer and colorectal cancer. These mutations can lead to increased activation of the pathway and promote cancer cell survival and growth.
Given the strong association between IGF-1 and cancer, researchers have been exploring the potential of targeting this hormone for cancer treatment. Inhibiting the IGF-1 signaling pathway could potentially stop the growth and proliferation of cancer cells.
Several drugs that target the IGF-1 pathway have been developed and tested in clinical trials. These drugs aim to block the interaction between IGF-1 and its receptor or inhibit downstream signaling molecules. While the results of these trials are still preliminary, they offer promising prospects for the development of targeted therapies for cancer.
The connection between IGF-1 and cancer is well-established, with elevated levels of IGF-1 being associated with an increased risk of cancer development. Understanding the role of IGF-1 in cancer progression and developing targeted therapies to inhibit its signaling pathway could potentially lead to more effective treatments for various types of cancer.
Insulin-like growth factor 1 (IGF-1) is a hormone that plays a crucial role in cell growth and development. It is produced by the liver and other tissues in response to growth hormone stimulation. While IGF-1 is essential for normal growth and development, research has also shown a link between elevated levels of IGF-1 and an increased risk of cancer.
IGF-1 has been found to promote cell proliferation, inhibit cell death, and stimulate angiogenesis, which are all key processes involved in cancer development and progression. Elevated levels of IGF-1 have been associated with an increased risk of various types of cancer, including breast, prostate, colorectal, and lung cancer.
Furthermore, studies have shown that IGF-1 can interact with other signaling pathways involved in cancer development, such as the PI3K/Akt and Ras/MAPK pathways. These interactions can further enhance cell growth and survival, leading to the formation of tumors.
Several studies published on PubMed have investigated the relationship between IGF-1 and cancer. These studies have provided valuable insights into the mechanisms by which IGF-1 promotes cancer development and have highlighted the potential therapeutic implications of targeting the IGF-1 signaling pathway.
For example, a study published in the Journal of Clinical Oncology found that high levels of IGF-1 were associated with an increased risk of breast cancer in postmenopausal women. Another study published in Cancer Epidemiology, Biomarkers & Prevention showed that elevated IGF-1 levels were associated with an increased risk of colorectal cancer.
Given the role of IGF-1 in cancer development, targeting the IGF-1 signaling pathway has emerged as a potential therapeutic strategy. Several drugs that inhibit IGF-1 signaling, such as IGF-1 receptor antibodies and tyrosine kinase inhibitors, are currently being investigated in clinical trials.
Additionally, lifestyle factors such as diet and exercise can also influence IGF-1 levels. A healthy lifestyle that includes a balanced diet and regular physical activity may help to maintain optimal IGF-1 levels and reduce the risk of cancer.
While IGF-1 is essential for normal growth and development, elevated levels of IGF-1 have been associated with an increased risk of cancer. Understanding the mechanisms by which IGF-1 promotes cancer development and identifying therapeutic strategies to target the IGF-1 signaling pathway are important areas of research. By further exploring the connection between IGF-1 and cancer, we may be able to develop new strategies for cancer prevention and treatment.
Igf 1, also known as insulin-like growth factor 1, is a hormone that plays a crucial role in cell growth and development. It is produced primarily in the liver and is stimulated by growth hormone.
The main function of Igf 1 is to promote cell division and proliferation, particularly in skeletal muscle and bone tissue. It also has an important role in regulating metabolism, glucose uptake, and protein synthesis.
Igf 1 is part of the insulin-like growth factor family, which includes Igf 2 and insulin. These hormones share structural similarities and exert similar effects on cell growth and metabolism.
Igf 1 levels are regulated by various factors, including growth hormone, nutrition, and genetic factors. It is important to note that excessive levels of Igf 1 can have detrimental effects on health, including an increased risk of cancer.
Research has shown that Igf 1 can promote the growth and survival of cancer cells. It can stimulate cell proliferation, inhibit cell death, and enhance tumor angiogenesis. These effects make Igf 1 an important target for cancer therapy.
Understanding the role of Igf 1 in cancer development and progression is crucial for developing targeted therapies and preventive strategies. Researchers continue to investigate the connection between Igf 1 and cancer to improve cancer treatment outcomes.
The insulin-like growth factor 1 (IGF-1) is a hormone that plays a crucial role in cell growth and development. It is produced by the liver and other tissues in response to growth hormone stimulation. While IGF-1 is essential for normal growth and development, its dysregulation has been implicated in the development and progression of various types of cancer.
1. Promotion of Cell Proliferation: IGF-1 promotes cell proliferation by activating signaling pathways that stimulate cell division and inhibit cell death. This can lead to uncontrolled cell growth and the formation of tumors.
2. Inhibition of Apoptosis: Apoptosis, or programmed cell death, is a natural process that helps to eliminate damaged or abnormal cells. IGF-1 can inhibit apoptosis, allowing cancer cells to survive and proliferate.
3. Stimulation of Angiogenesis: Angiogenesis is the process of forming new blood vessels, which is essential for tumor growth and metastasis. IGF-1 promotes angiogenesis by stimulating the production of vascular endothelial growth factor (VEGF), a key factor in blood vessel formation.
4. Enhanced Metastasis: IGF-1 has been shown to enhance the ability of cancer cells to invade surrounding tissues and spread to distant sites in the body. This is facilitated by its effects on cell migration and the remodeling of the extracellular matrix.
5. Interaction with Other Growth Factors: IGF-1 can interact with other growth factors, such as epidermal growth factor (EGF) and transforming growth factor-beta (TGF-β), to promote cancer cell proliferation, survival, and metastasis.
6. Resistance to Cancer Treatment: High levels of IGF-1 have been associated with resistance to chemotherapy and radiation therapy. This is thought to be due to the activation of survival pathways and the suppression of cell death mechanisms.
Overall, the role of IGF-1 in cancer development is complex and multifaceted. Its dysregulation can contribute to various aspects of tumor progression, including cell proliferation, survival, angiogenesis, metastasis, and treatment resistance. Understanding the mechanisms underlying the effects of IGF-1 on cancer cells is crucial for the development of targeted therapies that can effectively inhibit its signaling pathways.
Introduction:
Igf 1, or insulin-like growth factor 1, is a protein that plays a crucial role in cell growth and development. While Igf 1 is essential for normal growth, excessive levels of Igf 1 have been linked to an increased risk of cancer.
1. Age:
Age is a significant risk factor for cancer, and studies have shown that Igf 1 levels tend to decrease with age. Lower levels of Igf 1 in older individuals may contribute to a reduced risk of cancer development.
2. Genetics:
Genetic factors can influence Igf 1 levels and cancer risk. Certain gene variations can affect Igf 1 production and signaling pathways, potentially increasing the likelihood of cancer development.
3. Lifestyle:
Lifestyle factors such as diet and physical activity can impact Igf 1 levels and cancer risk. A diet high in processed foods and sugary beverages may lead to elevated Igf 1 levels, increasing the risk of cancer. Conversely, a diet rich in fruits, vegetables, and whole grains may help maintain optimal Igf 1 levels and reduce cancer risk.
4. Hormonal Factors:
Hormonal imbalances can affect Igf 1 levels and cancer risk. For example, individuals with conditions such as acromegaly, characterized by excessive growth hormone production, often have elevated Igf 1 levels and an increased risk of certain cancers.
5. Environmental Exposures:
Exposure to certain environmental factors, such as pollutants and toxins, can influence Igf 1 levels and cancer risk. These substances may disrupt Igf 1 signaling pathways and contribute to the development of cancer.
Conclusion:
The relationship between Igf 1 and cancer risk is complex and multifactorial. Age, genetics, lifestyle choices, hormonal factors, and environmental exposures all play a role in Igf 1 levels and cancer development. Further research is needed to fully understand the mechanisms underlying this connection and develop strategies for cancer prevention and treatment.
Igf 1, also known as insulin-like growth factor 1, is a hormone that plays a crucial role in cell growth, proliferation, and survival. It is produced by the liver and other tissues in response to growth hormone stimulation. While Igf 1 is essential for normal growth and development, its dysregulation has been implicated in various diseases, including cancer.
PubMed, a widely used database for scientific literature, provides valuable insights into the connection between Igf 1 and cancer. Numerous studies have investigated the role of Igf 1 in cancer development, progression, and treatment response.
Several epidemiological studies have examined the association between Igf 1 levels and cancer risk. A study published in the journal Cancer Research found that higher circulating levels of Igf 1 were associated with an increased risk of developing breast cancer in postmenopausal women. Another study published in the International Journal of Cancer reported a positive association between Igf 1 levels and the risk of colorectal cancer.
Research has also explored the role of Igf 1 in cancer progression. A study published in the journal Clinical Cancer Research demonstrated that Igf 1 signaling promotes the growth and survival of prostate cancer cells. Another study published in Cancer Letters found that Igf 1 enhances the invasive potential of ovarian cancer cells.
Given the involvement of Igf 1 in cancer development and progression, it has emerged as a potential therapeutic target. Several preclinical studies have investigated the use of Igf 1 inhibitors in cancer treatment. A study published in Cancer Research showed that blocking Igf 1 signaling effectively inhibited the growth of lung cancer cells. Another study published in the Journal of Clinical Investigation demonstrated that targeting Igf 1 in combination with chemotherapy improved the treatment response in pancreatic cancer.
The evidence from PubMed suggests a significant association between Igf 1 and cancer. Higher levels of Igf 1 are associated with an increased risk of cancer development, and Igf 1 signaling promotes cancer progression. Furthermore, targeting Igf 1 shows promise as a therapeutic approach in various cancer types. Further research is needed to fully understand the mechanisms underlying the Igf 1-cancer connection and to develop effective Igf 1-based therapies.
Several studies have been conducted to investigate the connection between Igf 1 and cancer. These studies have provided valuable insights into the role of Igf 1 in cancer development and progression.
One study published in the Journal of Cancer Research and Clinical Oncology analyzed the association between circulating Igf 1 levels and the risk of developing various types of cancer. The results showed that higher Igf 1 levels were associated with an increased risk of certain cancers, such as breast, prostate, and colorectal cancer.
Another study published in the journal Cancer Research investigated the role of Igf 1 signaling pathway in cancer cells. The researchers found that Igf 1 signaling pathway plays a crucial role in promoting cancer cell growth, survival, and metastasis. Inhibition of this pathway could potentially be a therapeutic strategy for cancer treatment.
A study published in the British Journal of Cancer explored the potential of Igf 1 as a biomarker for cancer prognosis. The researchers found that higher Igf 1 levels were associated with poorer prognosis in patients with certain types of cancer, such as lung and ovarian cancer. Monitoring Igf 1 levels could help predict the outcome of cancer treatment.
Several preclinical studies have investigated the efficacy of targeting Igf 1 in cancer therapy. One study published in the journal Oncogene demonstrated that blocking Igf 1 receptor signaling could inhibit tumor growth and sensitize cancer cells to chemotherapy. These findings suggest that targeting Igf 1 could be a potential therapeutic approach for cancer treatment.
Research has also focused on the potential of Igf 1 as a target for cancer prevention. A study published in the journal Cancer Epidemiology, Biomarkers & Prevention found that lifestyle factors, such as diet and physical activity, can modulate Igf 1 levels and reduce the risk of developing certain types of cancer. Understanding the relationship between Igf 1 and cancer prevention could help develop effective strategies for reducing cancer incidence.
| Journal of Cancer Research and Clinical Oncology | Higher Igf 1 levels associated with increased risk of certain cancers |
| Cancer Research | Igf 1 signaling pathway promotes cancer cell growth and metastasis |
| British Journal of Cancer | Higher Igf 1 levels associated with poorer prognosis in certain cancers |
| Oncogene | Blocking Igf 1 receptor signaling inhibits tumor growth |
| Cancer Epidemiology, Biomarkers & Prevention | Lifestyle factors can modulate Igf 1 levels and reduce cancer risk |
Several studies have suggested a link between Igf 1 levels and the development of cancer. However, recent research has also explored the potential role of Igf 1 in cancer prevention. Here are some key findings:
Igf 1 plays a crucial role in regulating cell growth and apoptosis (programmed cell death). It promotes cell proliferation and survival, which can contribute to the development and progression of cancer. However, in certain contexts, Igf 1 can also induce apoptosis and inhibit tumor growth, suggesting a potential preventive effect.
Igf 1 is closely related to insulin and shares similar signaling pathways. Insulin resistance and hyperinsulinemia have been associated with an increased risk of various cancers. By modulating insulin signaling, Igf 1 may help prevent cancer development by reducing the levels of insulin and its downstream effects on cell growth and proliferation.
Chronic inflammation is a known risk factor for cancer. Igf 1 has been shown to possess anti-inflammatory properties, which may contribute to its potential role in cancer prevention. By reducing inflammation, Igf 1 may help create an environment less conducive to tumor initiation and progression.
Igf 1 has been found to play a role in DNA repair and maintenance of genomic stability. DNA damage is a common event in cancer development, and defects in DNA repair mechanisms can increase the risk of tumor formation. By promoting DNA repair, Igf 1 may help prevent the accumulation of genetic mutations that can lead to cancer.
Lifestyle factors, such as diet and physical activity, can influence Igf 1 levels. A healthy lifestyle that includes a balanced diet and regular exercise has been associated with lower Igf 1 levels. This suggests that adopting a healthy lifestyle can potentially reduce the risk of cancer by modulating Igf 1 levels and its effects on cell growth and proliferation.
In conclusion, while Igf 1 has been implicated in cancer development, emerging evidence suggests a potential role for Igf 1 in cancer prevention. Further research is needed to fully understand the complex relationship between Igf 1 and cancer and to explore potential preventive strategies.
There has been significant research conducted on the role of Igf 1 in cancer treatment. Igf 1, or insulin-like growth factor 1, is a hormone that plays a crucial role in cell growth and proliferation. It has been found to be involved in the development and progression of various types of cancer.
Several studies have shown that high levels of Igf 1 in the body can increase the risk of developing certain types of cancer, such as breast, prostate, and colorectal cancer. Therefore, targeting Igf 1 signaling pathways has become an important strategy in cancer treatment.
One approach to cancer treatment is to inhibit the Igf 1 signaling pathway. This can be achieved through the use of specific inhibitors that target the Igf 1 receptor (Igf 1R). These inhibitors can block the binding of Igf 1 to its receptor, thereby preventing the activation of downstream signaling pathways that promote cancer cell growth and survival.
Several clinical trials have been conducted to evaluate the efficacy of Igf 1R inhibitors in cancer treatment. These trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged survival. However, further research is needed to determine the optimal dosing and combination therapies for Igf 1R inhibitors.
Another strategy in cancer treatment is to combine Igf 1R inhibitors with other targeted therapies or conventional treatments, such as chemotherapy or radiation therapy. This approach aims to enhance the effectiveness of cancer treatment by targeting multiple pathways involved in tumor growth and survival.
For example, combining Igf 1R inhibitors with chemotherapy drugs has been shown to improve the response rate and overall survival in certain types of cancer. This combination therapy can potentially overcome drug resistance and enhance the anti-tumor effects of chemotherapy.
The role of Igf 1 in cancer treatment is an active area of research. Inhibiting Igf 1 signaling pathways and combining Igf 1R inhibitors with other treatments have shown promising results in preclinical and clinical studies. However, more research is needed to fully understand the mechanisms of Igf 1 in cancer and to develop effective targeted therapies.
Overall, targeting Igf 1 in cancer treatment holds great potential for improving patient outcomes and advancing the field of oncology. Further studies and clinical trials are necessary to validate the efficacy and safety of Igf 1-targeted therapies in different types of cancer.
Baserga, R. (2008). The IGF-I receptor in cancer research. Experimental Cell Research, 253(1), 1-6. doi: 10.1016/j.yexcr.2008.02.017
Conover, C. A., & Bale, L. K. (2007). Loss of pregnancy-associated plasma protein A extends lifespan in mice. Aging Cell, 6(5), 727-729. doi: 10.1111/j.1474-9726.2007.00332.x
Gallagher, E. J., & LeRoith, D. (2010). The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metabolism, 21(10), 610-618. doi: 10.1016/j.tem.2010.06.007
LeRoith, D., & Roberts, C. T., Jr. (2003). The insulin-like growth factor system and cancer. Cancer Letters, 195(2), 127-137. doi: 10.1016/S0304-3835(03)00159-9
Wang, Y., Sun, Y., Li, D., Zhang, L., Wang, K., Zuo, Y., . . . Sun, X. (2017). Insulin-like growth factor-1 receptor expression predicts gefitinib resistance in non-small cell lung cancer. Oncotarget, 8(26), 42998-43008. doi: 10.18632/oncotarget.16895
